Loading patent…
AssigneeAmgen Inc.
InventorsEric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Ai Ching Lim, Randal Robert Ketchum, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
Estimating the term…
Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
A human interleukin-2 (IL-2) mutein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO:1, wherein the IL-2 mutein has at least one mutation selected from H16A, H16G, H16K, H16M, H16R, H16S, H16T, H16V, and H16Y, and preferentially stimulates T regulatory cells relative to other T cells or NK cells.
Dependencies are inferred from the claim text.